Recombinant constructs of
View Patent ↗Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.
1. A method of delivering a chimeric protein comprising at least a first and a second polypeptide, wherein the N-terminus of the chimeric protien comprises the first polypeptide, wherein the first polypeptide comprises Borrelia burgdorferi OspC and wherein the second polypeptide comprises Borrelia burgdorferi OspA, comprising administering the chimeric protein to an animal.
2. The method of claim 1 , wherein the chimeric protein is administered with a physiologically-acceptable vehicle or carrier.
3. The method of claim 1 , wherein the chimeric protein is encoded by a nucleic acid selected from the group consisting of: SEQ ID NOs: 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.
4. The method of claim 1 , wherein the chimeric protein comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.
5. A method of immunizing an animal or human against Lyme disease, comprising administering a composition comprising a chimeric protein of at least a first and a second polypeptide, wherein the N-terminus of the chimeric protien comprises the first polypeptide, wherein the first polypeptide comprises Borrelia burgdorferi OspC and wherein the second polypeptide comprises Borrelia burgdorferi OspA.
6. The method of claim 5 , wherein the chimeric protein comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.